E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Relationship Between Activated Clotting Time and Ischemic or Hemorrhagic Complications Analysis of 4 Recent Randomized Clinical Trials of Percutaneous Coronary Intervention
Sorin J. Brener,David J. Moliterno,A. Michael Lincoff,Steven R. Steinhubl,Kathy E. Wolski,Eric J. Topol +5 more
TL;DR: In patients undergoing PCI with frequent stent and potent platelet inhibition use, ACT does not correlate with ischemic complications and has a modest association with bleeding complications, driven mainly by minor bleeding.
Journal ArticleDOI
Towards precise classification of cancers based on robust gene functional expression profiles
Zheng Guo,Zheng Guo,Zheng Guo,Tianwen Zhang,Xia Li,Xia Li,Xia Li,Qi Wang,Jianzhen Xu,Hui Yu,Jing Zhu,Haiyun Wang,Chenguang Wang,Eric J. Topol,Qing Kenneth Wang,Shaoqi Rao,Shaoqi Rao +16 more
TL;DR: Inspired by the insight that genes act as a module to carry out a highly integrated cellular function, this modular approach is demonstrated to be a powerful alternative approach to analyzing high dimension micro array data and is robust to high measurement noise and intrinsic biological variance inherent in microarray data.
Journal ArticleDOI
Lack of Evidence of a Clopidogrel–Statin Interaction in the CHARISMA Trial
Jacqueline Saw,Danielle M. Brennan,Steven R. Steinhubl,Deepak L. Bhatt,Koon-Hou Mak,Keith A.A. Fox,Eric J. Topol,Charisma Investigators +7 more
TL;DR: The CHARISMA trial as discussed by the authors evaluated the potential impact of clopidogrel and statin interaction in a randomized, placebo-controlled trial with long-term follow-up.
Journal ArticleDOI
Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction.
Robert M. Califf,Eric J. Topol,Barry S. George,Jane M. Boswick,Charles W. Abbottsmith,Kristina N. Sigmon,Richard J. Candela,Ramona Masek,Dean J. Kereiakes,William W. O'Neill,Richard S. Stack,David C. Stump +11 more
TL;DR: Careful clinical evaluation may improve assessment of the risk/benefit ratio of thrombolytic therapy and among the patient descriptors examined, lighter weight, older age, female sex, and history of hypertension were associated with greater blood loss.